VBI Vaccines Inc (VBIV) NPV
VBI Vaccines Inc. (VBI) is a biopharmaceutical company. VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is focused on targeting and overcoming infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). The Company’s products include 3-antigen hepatitis B virus (HBV) Vaccine Candidate; VBI-2900, which is a coronavirus vaccine program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901 GBM. The Company is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901. It is also conducting the Phase I clinical study of prophylactic COVID-19 vaccine candidate, VBI-2902 and clinical study with VBI-2905, COVID-19 vaccine candidate against the Beta variant.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.